Rennes University Hospital: Sclerosis trials

The registry lists 13 Sclerosis studies with Rennes University Hospital as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 1Phase 3 3No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Defining an Immunological Signature Related to Lesion Location in Multiple SclerosisCompletedNCT05326048
• IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple SclerosisCompletedNCT04697407Not applicable
• Investigation of Novel Immunological Biomarkers by Mass Cytometry in Patients With Early Multiple Sclerosis (CISCO)CompletedNCT04510350
• MUltiple Sclerosis : T Cell / B Cell ExplorationCompletedNCT04231253
• Systemic Sclerosis and Jak Inhibitors : Emphasis on MacrophagesActive, not recruitingNCT04206644
• RElevance of UltraSonography for Assessing Salivary Gland Involvement in Systemic Sclerosis (SSc)CompletedNCT04001556Not applicable
• Validation of a Self-questionnaire in French on the Use of the Upper Limbs in Patients With Multiple SclerosisCompletedNCT03655093
• Clinical Decision Support System (CADIMS) for MS DiagnosticCompletedNCT03205280
• National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple SclerosisCompletedNCT02937285Phase 3
• The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.TerminatedNCT01567553
• Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) RelapsesStatus unknownNCT00984984Phase 3
• Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis PatientsCompletedNCT00280592Phase 3
• Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple SclerosisTerminatedNCT00219908Phase 2